To adapt to the hypo-vascular nature of pancreatic cancer, which is usually characterized by oxygen and nutrient deficiency, oncogenic KRAS promotes glucose transporter (GLUT1) and hexokinase gene transcription to enhance glucose transport and utilization [8]. Here, KRAS is linked to pancreatic neoplasm.